0001209191-23-004148.txt : 20230119 0001209191-23-004148.hdr.sgml : 20230119 20230119214843 ACCESSION NUMBER: 0001209191-23-004148 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230117 FILED AS OF DATE: 20230119 DATE AS OF CHANGE: 20230119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Andriole Michael T. CENTRAL INDEX KEY: 0001698751 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35867 FILM NUMBER: 23538786 MAIL ADDRESS: STREET 1: C/O ENDOCYTE, INC. STREET 2: 3000 KENT AVENUE, SUITE A1-100 CITY: WEST LAFAYETTE STATE: IN ZIP: 47906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHIMERIX INC CENTRAL INDEX KEY: 0001117480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330903395 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919.806.1074 MAIL ADDRESS: STREET 1: 2505 MERIDIAN PARKWAY, SUITE 100 CITY: DURHAM STATE: NC ZIP: 27713 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-17 0 0001117480 CHIMERIX INC CMRX 0001698751 Andriole Michael T. 2505 MERIDIAN PARKWAY, SUITE 100 DURHAM NC 27713 0 1 0 0 Chief Business Officer and CFO Common Stock 2023-01-17 4 A 0 32175 0.00 A 294899 D Stock Option (Right to Buy) 1.97 2023-01-17 4 A 0 192825 0.00 A 2033-01-16 Common Stock 192825 192825 D The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 8,043 shares subject to the RSUs will vest on the one-year anniversary of the date of grant, 8,043 shares subject to the RSUs will vest on the second-year anniversary of the date of grant, 8,043 shares subject to the RSUs will vest on the third-year anniversary of the date of grant, and 8,046 shares subject to the RSUs will vest on the fourth-year anniversary of the date of grant. 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. /s/ Michael Alrutz, Attorney-in-Fact 2023-01-19